
HMB with exercise in older adults: fresh trial positive, new meta-analysis negative
A 2026 frailty trial reported functional gains from HMB, while a 2026 meta-analysis found no routine benefit with resistance training.
HMB may help selected frail or sarcopenic groups, but pooled evidence does not support routine use for all older adults who can resistance train.
Two 2026 publications point in different directions
Beta-hydroxy-beta-methylbutyrate, or HMB, is a leucine metabolite sold for preserving muscle. In 2026, a randomized trial in older adults with frailty reported added functional benefits when HMB was combined with multicomponent exercise. A separate 2026 meta-analysis found no advantage for body composition or strength when HMB was added to resistance training across adults aged 50 and older.
The apparent conflict is not necessarily an error. A frail hospital-associated population and generally exercise-capable older adults are different groups. Outcomes, formulations, nutritional status and program design can change the estimated effect.

The frailty trial reported better physical performance
The double-blind trial enrolled 136 older adults with frailty. Both groups completed exercise, while one received three grams of calcium HMB daily and the other maltodextrin placebo for 12 weeks. The HMB group improved more on the Short Physical Performance Battery and some walking, daily-function and muscle-mass measures.
Not every outcome favored HMB. Chair-stand and handgrip results did not differ significantly, and the timed-up-and-go analysis was not uniformly positive. A balanced summary should report the outcome pattern rather than describing the intervention as a general strength enhancer.
The pooled resistance-training evidence was negative
A 2026 meta-analysis combined thirteen randomized trials with 561 participants aged 50 or older. Adding HMB to resistance training did not improve fat mass, muscle mass or muscle strength. Strength results were heterogeneous, meaning study estimates varied substantially.
Another recent review reported possible modest gains in handgrip and overall physical performance but no consistent change in gait speed or lean mass, with half the included trials rated high risk of bias. Review conclusions depend on selected outcomes and statistical methods, so the underlying population and trial quality remain decisive.
Frailty, sarcopenia and healthy aging are not synonyms
A small 2023 trial in adults with sarcopenia found gains in grip, gait and chair-stand performance when HMB was added to exercise. By contrast, a 156-woman factorial trial found exercise benefits but no significant HMB interaction for the primary muscle-mass outcome. These studies should not be combined into a universal older-adult claim.
Low intake, acute illness, frailty and diagnosed sarcopenia may create different opportunities from routine supplementation in well-nourished exercisers. A product label rarely captures those distinctions, but clinical applicability depends on them.

Where the evidence leaves practice
HMB should not replace protein adequacy, progressive exercise or evaluation of unintentional weight and muscle loss. Combination products containing vitamin D, calcium or protein make attribution more difficult and may duplicate other supplements. Kidney function, medicines and overall nutrition belong in professional review.
The freshest evidence supports a targeted research question rather than routine use. HMB may add value in selected frail or sarcopenic populations under structured care, while broad resistance-training data remain unconvincing. Future trials should prespecify functional outcomes, report adherence and determine whether improvements persist after supplementation ends.
Functional goals should determine the next study
For a frail adult, a modest change in balance, walking distance or independence may matter more than a small shift in lean mass. Future HMB trials should define a patient-important primary outcome, state the meaningful threshold in advance and track falls, hospitalization and sustained daily function. Body-composition measures alone cannot establish improved mobility.
Researchers should also report protein and energy intake, vitamin D status, exercise progression and adherence, because HMB may appear different in undernourished and well-nourished participants. Stratified analyses should be planned rather than discovered after results are known. This would clarify whether the positive frailty finding identifies a responsive subgroup or represents an isolated estimate within a mixed literature. Studies should compare calcium HMB with free-acid formulations only when the design supports that question. Cost, pill burden and gastrointestinal tolerance also matter when an intervention is proposed for months. A statistically positive performance score should be translated into whether participants notice greater independence. Durability after stopping should be measured too.
Sources & further reading
- Exercise training plus HMB in older adults with frailty: 2026 randomized trial ↗
- HMB supplementation as an adjunct to resistance training in older adults: 2026 meta-analysis ↗
- HMB in older adults with sarcopenia: randomized placebo-controlled study ↗
- Exercise and HMB in older women with low muscle mass: randomized factorial trial ↗
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.